{"aliases":[{"type":"USBrandName","name":"Actemra"},{"type":"ForeignBrandName","name":"RoActemra"},{"type":"Abbreviation","name":"MRA"},{"type":"CodeName","name":"R-1569"},{"type":"CASRegistryName","name":"375823-41-9"},{"type":"Synonym","name":"immunoglobulin G1, anti-(human interleukin 6 receptor) (human-mouse monoclonal MRA heavy chain), disulfide with human-mouse monoclonal MRA kappa-chain, dimer"}],"definition":{"html":"A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions.","text":"A recombinant, humanized IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R) with immunosuppressant activity. Tocilizumab targets and binds to both the soluble form of IL-6R (sIL-6R) and the membrane-bound form (mIL-6R), thereby blocking the binding of IL-6 to its receptor. This prevents IL-6-mediated signaling. IL-6, a pro-inflammatory cytokine that plays an important role in the regulation of the immune response, is overproduced in autoimmune disorders, certain types of cancers and possibly various other inflammatory conditions."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/tocilizumab","text":"Tocilizumab"},"nciConceptId":"C84217","nciConceptName":"Tocilizumab","termId":713832,"name":"tocilizumab","firstLetter":"t","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"tocilizumab"}